Brokerages Anticipate Achillion Pharmaceuticals, Inc. (ACHN) to Post -$0.13 EPS

Share on StockTwits

Analysts expect Achillion Pharmaceuticals, Inc. (NASDAQ:ACHN) to report earnings of ($0.13) per share for the current fiscal quarter, according to Zacks. Zero analysts have provided estimates for Achillion Pharmaceuticals’ earnings. Achillion Pharmaceuticals posted earnings per share of ($0.15) during the same quarter last year, which indicates a positive year over year growth rate of 13.3%. The company is expected to announce its next earnings report on Wednesday, May 1st.

On average, analysts expect that Achillion Pharmaceuticals will report full year earnings of ($0.57) per share for the current year, with EPS estimates ranging from ($0.58) to ($0.55). For the next financial year, analysts expect that the firm will report earnings of ($0.74) per share, with EPS estimates ranging from ($0.84) to ($0.63). Zacks Investment Research’s earnings per share averages are an average based on a survey of sell-side research firms that cover Achillion Pharmaceuticals.

Achillion Pharmaceuticals (NASDAQ:ACHN) last posted its quarterly earnings results on Thursday, March 7th. The biopharmaceutical company reported ($0.12) earnings per share (EPS) for the quarter, topping the consensus estimate of ($0.15) by $0.03.

Several equities analysts recently issued reports on ACHN shares. BidaskClub upgraded Achillion Pharmaceuticals from a “hold” rating to a “buy” rating in a research report on Friday, February 22nd. ValuEngine upgraded Achillion Pharmaceuticals from a “sell” rating to a “hold” rating in a research report on Wednesday, January 2nd. Zacks Investment Research upgraded Achillion Pharmaceuticals from a “sell” rating to a “hold” rating in a research report on Thursday, January 24th. Finally, William Blair restated an “outperform” rating on shares of Achillion Pharmaceuticals in a research report on Thursday, March 7th. Three research analysts have rated the stock with a hold rating, one has given a buy rating and one has given a strong buy rating to the stock. The company has a consensus rating of “Buy” and a consensus target price of $4.50.

ACHN opened at $3.13 on Tuesday. Achillion Pharmaceuticals has a 1 year low of $1.29 and a 1 year high of $4.06. The company has a market cap of $414.76 million, a P/E ratio of -6.14 and a beta of 2.45.

Several hedge funds have recently modified their holdings of ACHN. Northern Trust Corp grew its position in shares of Achillion Pharmaceuticals by 1.9% in the 2nd quarter. Northern Trust Corp now owns 1,604,822 shares of the biopharmaceutical company’s stock worth $4,541,000 after buying an additional 30,669 shares during the last quarter. JPMorgan Chase & Co. grew its position in shares of Achillion Pharmaceuticals by 7.1% in the 3rd quarter. JPMorgan Chase & Co. now owns 1,039,438 shares of the biopharmaceutical company’s stock worth $3,825,000 after buying an additional 69,270 shares during the last quarter. BlackRock Inc. grew its position in shares of Achillion Pharmaceuticals by 0.5% in the 3rd quarter. BlackRock Inc. now owns 11,925,359 shares of the biopharmaceutical company’s stock worth $43,885,000 after buying an additional 61,683 shares during the last quarter. Dimensional Fund Advisors LP grew its position in shares of Achillion Pharmaceuticals by 4.2% in the 3rd quarter. Dimensional Fund Advisors LP now owns 7,182,715 shares of the biopharmaceutical company’s stock worth $26,433,000 after buying an additional 290,531 shares during the last quarter. Finally, Connor Clark & Lunn Investment Management Ltd. grew its position in shares of Achillion Pharmaceuticals by 20.0% in the 3rd quarter. Connor Clark & Lunn Investment Management Ltd. now owns 122,757 shares of the biopharmaceutical company’s stock worth $452,000 after buying an additional 20,450 shares during the last quarter. Hedge funds and other institutional investors own 75.22% of the company’s stock.

Achillion Pharmaceuticals Company Profile

Achillion Pharmaceuticals, Inc, a biopharmaceutical company, discovers, develops, and commercializes small molecule drug therapies for immune system disorders in the United States. Its lead drug candidate includes ACH-4471, an inhibitor of factor D that is Phase II clinical trials for patients with paroxysmal nocturnal hemoglobinuria and C3 glomerulopathy.

Featured Story: Cryptocurrencies

Get a free copy of the Zacks research report on Achillion Pharmaceuticals (ACHN)

For more information about research offerings from Zacks Investment Research, visit Zacks.com

Earnings History and Estimates for Achillion Pharmaceuticals (NASDAQ:ACHN)

Receive News & Ratings for Achillion Pharmaceuticals Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Achillion Pharmaceuticals and related companies with MarketBeat.com's FREE daily email newsletter.



Latest News

Telcoin Price Tops $0.0006 on Major Exchanges
Telcoin Price Tops $0.0006 on Major Exchanges
Crystal Clear  Market Capitalization Tops $26,650.00
Crystal Clear Market Capitalization Tops $26,650.00
SwissBorg  Market Cap Tops $5.04 Million
SwissBorg Market Cap Tops $5.04 Million
OAX Price Hits $0.23 on Major Exchanges
OAX Price Hits $0.23 on Major Exchanges
Haven Protocol Price Tops $0.44 on Top Exchanges
Haven Protocol Price Tops $0.44 on Top Exchanges
SUQA  24 Hour Volume Hits $17,144.00
SUQA 24 Hour Volume Hits $17,144.00


© 2006-2019 Ticker Report